BioStock: Abliva secures funding to advance KL1333 into phase II/III

It has undeniably been an eventful week for Swedish biotech Abliva. On Tuesday, the company, whose focus is primary mitochondrial diseases, announced that they are conducting a 200 MSEK financing round. The bulk of the raised capital will be used to finance the upcoming registrational phase II/III trial with lead candidate KL1333.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/06/abliva-secures-funding-to-advance-kl1333-into-phase-ii-iii/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se